HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yae Kanai Selected Research

Precancerous Conditions

12/2010Genetic and epigenetic alterations during renal carcinogenesis.
7/2006Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues.
7/2005Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas.
11/2004Alterations in gene expression associated with the overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, during human hepatocarcinogenesis.
7/2003Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas.
7/2003Cell adhesion system and human cancer morphogenesis.
7/2002Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yae Kanai Research Topics

Disease

85Neoplasms (Cancer)
01/2022 - 09/2002
25Carcinogenesis
01/2018 - 03/2003
14Carcinoma (Carcinomatosis)
01/2019 - 09/2002
11Neoplasm Metastasis (Metastasis)
01/2021 - 08/2002
10Hepatocellular Carcinoma (Hepatoma)
04/2015 - 07/2002
8Stomach Neoplasms (Stomach Cancer)
01/2022 - 03/2003
8Adenocarcinoma of Lung
01/2021 - 09/2005
8Leiomyosarcoma
03/2020 - 08/2010
7Urinary Bladder Neoplasms (Bladder Cancer)
01/2016 - 08/2003
7Precancerous Conditions
12/2010 - 07/2002
7Chromosomal Instability (Chromosome Stability)
06/2010 - 07/2002
6Lung Neoplasms (Lung Cancer)
02/2020 - 06/2008
6Renal Cell Carcinoma (Grawitz Tumor)
12/2015 - 02/2003
6Colorectal Neoplasms (Colorectal Cancer)
04/2014 - 03/2003
4Adenocarcinoma
03/2014 - 04/2005
4Transitional Cell Carcinoma
07/2005 - 04/2003
3Breast Neoplasms (Breast Cancer)
07/2020 - 09/2002
3Squamous Cell Carcinoma of Head and Neck
03/2016 - 09/2009
3Pancreatic Neoplasms (Pancreatic Cancer)
03/2014 - 06/2010
3Leiomyoma (Uterine Fibroids)
09/2011 - 08/2010
3Ductal Carcinoma
07/2010 - 07/2005
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/2007 - 09/2004
3Fibrosis (Cirrhosis)
11/2004 - 07/2002
3Chronic Hepatitis (Chronic Active Hepatitis)
11/2004 - 07/2002
2Infections
06/2022 - 01/2017
2Inflammation (Inflammations)
01/2020 - 01/2014
2Hypoxia (Hypoxemia)
04/2015 - 01/2013
2Adenoma (Adenomas)
04/2013 - 03/2013
2Microsatellite Instability
03/2013 - 02/2012
2Prostatic Neoplasms (Prostate Cancer)
01/2013 - 10/2009
2Hyperplasia
10/2010 - 10/2005
2Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar)
10/2010 - 10/2005
2Lobular Carcinoma
07/2010 - 06/2004
2Ovarian Neoplasms (Ovarian Cancer)
07/2008 - 08/2007
2Carcinoma in Situ
12/2003 - 04/2003
1T-Cell Lymphoma (Lymphoma, T Cell)
06/2022
1Kidney Neoplasms (Kidney Cancer)
02/2021
1Ascites
01/2021
1Hepatitis
10/2020
1Colonic Neoplasms (Colon Cancer)
07/2020
1Endometrial Neoplasms (Endometrial Cancer)
07/2020
1Neonatal Sepsis
01/2020

Drug/Important Bio-Agent (IBA)

29DNA (Deoxyribonucleic Acid)IBA
02/2021 - 07/2002
23Proteins (Proteins, Gene)FDA Link
02/2019 - 07/2003
15Messenger RNA (mRNA)IBA
10/2020 - 07/2002
15MethyltransferasesIBA
03/2016 - 07/2002
14Biomarkers (Surrogate Marker)IBA
01/2019 - 04/2010
13Biological ProductsIBA
01/2018 - 07/2003
8Cadherins (E-Cadherin)IBA
01/2008 - 04/2003
6MicroRNAs (MicroRNA)IBA
04/2017 - 06/2009
6Indicators and Reagents (Reagents)IBA
03/2016 - 12/2004
5Pharmaceutical PreparationsIBA
03/2020 - 04/2013
4CateninsIBA
01/2019 - 07/2003
4EnzymesIBA
04/2015 - 12/2003
4beta CateninIBA
01/2008 - 07/2003
3ParaffinIBA
05/2021 - 10/2006
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2020 - 01/2007
3CarcinogensIBA
01/2018 - 10/2005
3DecitabineFDA Link
09/2015 - 01/2004
3ChromatinIBA
12/2013 - 12/2007
3DNA Methyltransferase 3BIBA
05/2012 - 11/2004
3AntigensIBA
01/2012 - 07/2005
3Hormones (Hormone)IBA
09/2011 - 08/2010
3hydrogen sulfite (bisulfite)IBA
07/2006 - 02/2004
2Formaldehyde (Formol)FDA Link
05/2021 - 09/2009
2Small Interfering RNA (siRNA)IBA
01/2021 - 06/2008
2Transforming Growth Factors (Transforming Growth Factor)IBA
01/2021 - 02/2020
2AntibodiesIBA
02/2020 - 12/2017
2InterferonsIBA
02/2020 - 12/2015
2Glutamate-Ammonia Ligase (Glutamine Synthetase)IBA
01/2019 - 04/2011
2Epithelial Cell Adhesion MoleculeIBA
01/2019 - 10/2014
2Lysine (L-Lysine)FDA Link
03/2016 - 04/2015
2Histones (Histone)IBA
03/2016 - 01/2014
2RNA (Ribonucleic Acid)IBA
12/2014 - 08/2003
2Cell Adhesion MoleculesIBA
06/2012 - 01/2011
2Proteasome Endopeptidase Complex (Proteasome)IBA
09/2011 - 08/2010
2CXC ChemokinesIBA
01/2011 - 01/2007
2Peptide Nucleic AcidsIBA
01/2010 - 11/2007
2A-factor (Streptomyces)IBA
07/2008 - 08/2007
2Proliferating Cell Nuclear Antigen (PCNA)IBA
06/2007 - 02/2004
2Transcription Factors (Transcription Factor)IBA
10/2006 - 08/2003
2ErbB Receptors (EGF Receptor)IBA
10/2005 - 09/2005
2Glycoproteins (Glycoprotein)IBA
04/2005 - 07/2003
2HeterochromatinIBA
01/2005 - 09/2002
2Tyrosine (L-Tyrosine)FDA Link
06/2004 - 07/2003
1Metalloproteases (Metalloproteinases)IBA
01/2021
1Poly(ADP-ribose) Polymerase InhibitorsIBA
07/2020
1PlatinumIBA
07/2020
1B7-H1 AntigenIBA
02/2020
1Toll-Like Receptor 4IBA
01/2020

Therapy/Procedure

16Therapeutics
06/2022 - 12/2007
2Drug Therapy (Chemotherapy)
06/2022 - 11/2012
2Immunotherapy
08/2019 - 12/2017
2Pancreaticoduodenectomy
03/2014 - 01/2014
2Cystectomy
04/2013 - 11/2012
2Lasers (Laser)
10/2006 - 09/2005
1Gastrectomy
01/2022
1Genomic Medicine
11/2021
1Salpingo-oophorectomy
07/2020
1Hysterectomy
07/2020